Keytruda

World Lung 2021 – front-line competition lines up behind Keytruda
World Lung 2021 – front-line competition lines up behind Keytruda
EP Vantage
World Lung
Merck
Keytruda
CStone Pharmaceuticals
Shanghai Junshi Biosciences
lung cancer
Flag link:
Merck Investors Have Reason to Cheer This Label Expansion
Merck Investors Have Reason to Cheer This Label Expansion
Motley Fool
Merck
Keytruda
Japan
triple negative breast cancer
Flag link:
Merck's Keytruda survives FDA scrutiny in bladder cancer, but ends up with a smaller label
Merck's Keytruda survives FDA scrutiny in bladder cancer, but ends up with a smaller label
Fierce Pharma
Merck
Keytruda
FDA
bladder cancer
Flag link:
The sellside’s most controversial products
The sellside’s most controversial products
EP Vantage
Merck
Keytruda
Biogen
Aduhelm
Pfizer
Vir Biotechnology
Flag link:
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
FDA
Cara Therapeutics
Vifor Pharma
Korsuva
Kadmon
belumosudil
Bristol Myers Squibb
Opdivo
Merck
Eisai
Keytruda
Flag link:
GSK's Jemperli follows Merck's Keytruda with FDA nod to target certain tumors regardless of location
GSK's Jemperli follows Merck's Keytruda with FDA nod to target certain tumors regardless of location
Fierce Pharma
GSK
Jemperli
FDA
cancer
Merck
Keytruda
Flag link:
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Flag link:
FDA starts speedy review of Keytruda for adjuvant kidney cancer
FDA starts speedy review of Keytruda for adjuvant kidney cancer
Pharmaforum
Merck
FDA
Keytruda
kidney cancer
Flag link:
Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers
Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers
Endpoints
Keytruda
Merck
clinical trials
melanoma
Flag link:
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
EP Vantage
FDA
Axsome Therapeutics
Sanofi
Merck
Pompe disease
depression
kidney cancer
Keytruda
Flag link:
Merck rebounds to win a milestone immunotherapy approval in early breast cancer
Merck rebounds to win a milestone immunotherapy approval in early breast cancer
BioPharma Dive
FDA
Merck
Keytruda
breast cancer
Flag link:
Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer
Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer
Endpoints
Merck
Keytruda
Lenvima
endometrial cancer
FDA
Flag link:
The top 15 blockbuster patent expirations coming this decade
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Flag link:
FDA Expands Approval for Keytruda in Locally Advanced Cutaneous SCC
FDA Expands Approval for Keytruda in Locally Advanced Cutaneous SCC
BioSpace
Merck
Keytruda
cutaneous squamous cell carcinoma
FDA
Flag link:
Merck to withdraw dangling accelerated approval for Keytruda in third-line stomach cancer
Merck to withdraw dangling accelerated approval for Keytruda in third-line stomach cancer
Endpoints
Merck
Keytruda
oncology
stomach cancer
FDA
Flag link:
Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study
Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study
BioSpace
Merck
Alpine Immune Sciences
cancer
ALPN-202
Keytruda
Flag link:
Merck's Keytruda extends life for cervical cancer patients in first-in-class win
Merck's Keytruda extends life for cervical cancer patients in first-in-class win
Fierce Pharma
Merck
Keytruda
cervical cancer
clinical trials
Flag link:
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer
Fierce Pharma
ASCO 2021
Merck
Keytruda
kidney cancer
Sutent
Pfizer
Flag link:
Xilio inks Merck deal to run checkpoint inhibitor combo trial
Xilio inks Merck deal to run checkpoint inhibitor combo trial
Fierce Biotech
Xilio Therapeutics
Merck
Keytruda
XTX101
clinical trials
solid tumors
Flag link:
Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone
Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone
Endpoints
Merck
Keytruda
ASCO 2021
Flag link:

Pages